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Introduction: Carbapenem-resistant Klebsiella pneumoniae are resistant to multiple classes of 
antibiotics and often necessitating the need for combination therapy to ensure adequate sustained 
killing activity and prevent the emergence of resistance. Previous in vitro studies have shown that the 
combination of colistin (COL) and ceftazidime/avibactam (CZA) resulted in sustained activity against 
Klebsiella pneumoniae. 
Methods: Five Klebsiella pneumoniae clinical isolates were utilized. (COL MIC: 0.5-32mg/L; CZA MIC: 0.5-
2mg/L).  COL (0.5, 1, 2, 4, 8, 16mg/L) and CZA (16/4, 32/8, 64/16, 128/32mg/L) were evaluated alone 
and in combination (COL 0.5, 1, 2, 4mg/L and CZA 16/4, 32/8, 64/16 mg/L) against an initial inoculum of 
~106 CFU/mL over 24 hours. Model development was conducted using a pooled approach with 
maximum likelihood estimation in ADAPT-5 and S-ADAPT-TRAN. 
Results: The mechanism-based model (MBM) characterized both drugs as exerting their 
pharmacological effect on the death rate of the bacteria. The MBM was able to capture the reduction in 
bacterial burden and rapid regrowth well (R2 = 0.974). The model precision was fair as characterized by 
parameter coefficient of variation.   
Conclusions: The MBM was able to capture the static time-kill experimental data well and help to better 
understand the effects of each drug in monotherapy and in combination. The model was accurately able 
to explain the killing effects of COL and CZA. This information will enable us to optimize and translate 
these antibiotic regimens to better fight infections caused by such hard-to-treat pathogens and prolong 
















Increasing spread of carbapenem resistance amongst Klebsiella pneumoniae is a worrisome, growing 
trend that is narrowing therapeutic options in clinic1,2, making blood stream infections (BSI) increasingly 
challenging to treat. BSIs in themselves are already associated with high mortality3, and substantial long-
term morbidity with no significant improvements despite attempts to optimize treatment4. Sepsis is a 
serious consequence of untreated or inadequately managed BSIs, in which the host’s inflammatory 
immune response causes life-threatening damage to the host’s organs and tissue5. Post-sepsis survivors 
experience a sharp increase in proportion of days spent in a clinical institution relative to days spent at 
home6, highlighting an apparent compromise in quality of life as a prominent survivorship issue. 
Presently, effective treatment of BSIs continues to be an obstacle in the clinic. 
In 2017, The World Health Organization ranked carbapenem-resistant (CRE) and 3rd generation 
cephalosporin-resistant Enterobacteriacae, including Klebsiella pneumoniae, at the top of their global 
priority list, citing that urgent research is required into development of new antibiotics for these 
resistant species7. Given the mounting resistance to newer antimicrobial agents, older antibiotics such 
as polymyxins are making a comeback. However, many of these agents have well-defined toxicities and 
side-effects that preclude intensive use in clinic8. While this pressure has borne fruit in the form of a 
novel class of beta-lactamase inhibitors such as avibactam and relebactam, a distinct lack of novel 
therapeutic agents in drug development pipeline remains a pervasive issue9. Given the challenging 
circumstances and in the interests of cost, clinicians have unsurprisingly turned towards using existing 
agents in combination to restore their antimicrobial activity, and improve therapeutic outcomes in 
patients with CRE infections. Previous in vitro studies demonstrated the success of ceftazidime-
avibactam (CZA) and colistin (COL) in monotherapy10. 
It is important to develop better mathematical models, metrics/pharmacodynamic analysis, and study 
designs to determine if combination therapy is efficacious and apply those results to clinical context. 
Mechanism-based modeling (MBM) can be useful in this because it takes into account the pharmacology 
of the drugs being used and this can help to better explain the effects that are being seen. Mechanism-
based modeling can also be used to optimize combination regimens for antibiotic agents to better 
understand how two drugs work together to achieve a maximum killing effect11. By applying 
pharmacodynamic (PD) modeling approaches to in vitro data, we can better understand how the 
combination of drugs work together and translate the results to useful dosing strategies in human 
patients. Developing a successful PD model can lead to other forms of optimization such as running 
simulations or using an in vitro dynamic model. 
The objective of this project was to develop a mechanism-based model informed by static concentration 
time-kill studies that characterizes the pharmacodynamic effect of colistin and ceftazidime/avibactam 







Five clinical BSI isolates of Klebsiella pneumoniae – culture ID 3138, 3135, 2873, 3207, 3173 were 
selected based on their clinical treatment group and minimum inhibitory concentration (MIC) profile 
from a total of 36 carbapenem-resistant isolates obtained from The Consortium on Resistance Against 
Carbapenems in Klebsiella and Other Enterobacteriacae (CRACKLE) study. Isolates were selected from 
each treatment category: colistin monotherapy, ceftazidime-avibactam monotherapy, and combination 
colistin and ceftazidime-avibactam. These isolates were also previously studied by van Duin et al. 
(2017)10. 
Medium and antibiotics 
Fresh stock solutions of all antibiotics were prepared in sterile water prior to each experiment and 
sterilized by filtration with a 0.22 µm filter (Olympus Plastics, Genesee Scientific) for susceptibility 
testing and in vitro static time-kill studies. Mueller-Hinton broth (BBL, Becton Dickinson, lot number 
8045582) supplemented with calcium (25 mg/L) and magnesium (12.5 mg/L) (SMHB) was used for 
susceptibility testing and in vitro static time-kill studies. Luria-Bertani (LB) broth (Difco, Becton 
Dickinson, lot number 4339957) similarly supplemented with calcium and magnesium (SLB) as above 
was used in bacterial culture for growth curve, and vesicle isolation, and purification processes. 
Avibactam (Advanced ChemBlocks Inc, lot number 10499), Ceftazidime hydrate (Sigma, lot number 
035M4897V), and Colistin sulfate salt (Sigma, SLBK0713V) were used for in vitro static time-kill assays. 
Susceptibility testing 
The MIC for the five clinical Klebsiella pneumoniae isolates with, ceftazidime-avibactam and colistin, 
were determined by broth microdilution in duplicates according to Clinical and Laboratory Standards 
Institute (CLSI) guidelines using cation-adjusted Mueller-Hinton broth (CAMHB). Broth microdilution was 
performed in 96-well polystyrene round bottom microwell plates (Thermo Fisher Scientific). Mueller-
Hinton agar (BBL, Becton Dickinson, lot number 8024807) was used for the agar dilution method. 
Susceptibility breakpoints for all antibiotics was guided by the British Society for Antimicrobial 
Chemotherapy (BSAC). 
In vitro static time-kill studies 
Static-concentration time-kill (SCTK) experiments were performed over 24 h to evaluate 
pharmacodynamic activity of colistin and ceftazidime-avibactam as monotherapy, and in combination 
against the five Klebsiella pneumoniae clinical isolates against a starting inoculum of 106 CFU/mL. 
Protein binding for colistin, ceftazidime, and avibactam were assumed to be 50%19, 10%, and 6.95% 
respectively based on published data12,13. Free drug concentrations for colistin  that were simulated 
included 0.5, 1, 2, 4, 8, and 16 mg/L, and free drug concentrations for ceftazidime with a constant 4 to 1 
ratio of  avibactam included 16/4, 32/8, 64/16, 128/32 mg/L. In combination, clinically-relevant free 
drug colistin concentrations of 0.5, 1, 2, and 4 mg/L were paired with a range of ceftazidime-avibactam 
concentrations of 16/4, 32/8, and 64/16 mg/L. The range of concentrations selected were used to assess 
a range of free drug concentrations that were in the therapeutic and supra-therapeutic range. 
Samples were obtained at 0, 1, 2, 4, 6, 8, and 24 hours, subject to dilutions with sterile saline as 
necessary. Viable bacterial counts were determined by plating 50 µL of each sample on drug-free 
Mueller-Hinton agar (BBL, Becton Dickinson, lot number 8024807) plates using an automatic WASP2 
spiral plater (Microbiology International). Plates were incubated for 24 h at 37°C before colony counts 
were determined using ProtoCOL SR (Symbiosis). The colony count in log10CFU/mL was plotted as a 
function of time for all tested drug regimens for each clinical isolate. 
Pharmacodynamic Model Development:  
The log10-transformed counts of CFU in response to concentrations of colistin and 
ceftazidime/avibactam were characterized by fitting candidate PD models. The PD model was derived by 
fitting smooth curves through the time-kill experimental data, resulting in the computation of model 
parameter values which summarize and characterize the observed experimental data and which are 
more amenable to hypothesis testing. PD models explored included one where the drug effect for either 
or both drugs was hypothesized to inhibit bacterial replication and where the drug effect enhanced the 
rate of bacterial killing. Models with two, three, or four preexisting bacterial populations were 
considered. Model development was conducted using a pooled approach with maximum likelihood 
estimation using ADAPT-514 and S-ADAPT-TRAN15. The differential equation solver used was LSODA and 
the function minimization was carried out using Nelder Mead Simplex. Model discrimination was 
accomplished using the rule of parsimony and the Akaike Information criteria (AIC) values, goodness of 
fit plots, parameter estimates and their coefficient of variation (CV%).  
Mechanism-based Model:  
This mechanism-based PD model of SCTK data was developed to quantitatively characterize the 
bacterial killing and regrowth for both colistin and ceftazidime/avibactam alone and in combination 
against Klebsiella pneumoniae. The total bacteria concentration was the difference between a saturable 
capacity-limited bacterial replication process and the rate of bacterial death due to natural elimination 
(elimination of bacteria in the absence of drug) (Kd; hour-1), the first-order bacterial elimination rate 
constant. The rate of bacterial replication described as the maximal velocity of bacterial growth [VGmax 
expressed as CFU/mL per hour] was parameterized as the maximum bacterial population size 
(CFUmax) and the median effect, (CFUm; CFU/mL), the bacterial density that results in half maximal rate 
of bacterial growth:   
 
VGMAX = KD*(CFUM+CFUMAX)  
 
We modeled monotherapy time-kill data for each antibiotic and the final estimates were used to inform 
the development of the model for the combination therapy. For the combination therapy, evaluated 
two significant interactions: (i) Outer membrane effect: colistin causes disruption of the outer 
membrane of the gram-negative bacteria that enhances the penetration of ceftazidime into the 
bacterial cell. (ii) Protective effect: avibactam provides effective protection provided against hydrolysis 
of ceftazidime by chromosomal and plasmidic β-lactamases. Mechanistic synergy was incorporated into 
the model by assuming an increase in target site penetration of ceftazidime due to disruption of the 
outer membrane by colistin.16 The avibactam beta-lactamase effect was incorporated into the model 
based on its activity against known Ambler class A (ESBL and KPC), C (AmpC), D (OXA-48) enzymes.17  
 
outer_membrane_effect_COL = 1-(IMAX_COL*COL**H_COL/(IC50_COL**H_COL+COL**H_CH))  
beta_lactamase_effect_AVI = 1-((IMAX_AVI*AVI**H_AVI)/(AVI**H_AVI+IC50_AVI**H_AVI))  
COL_Effect_R = (EMAX_COL*COL**H_COL)/(EC50_CR**H_COL+COL**H_COL)  
COL_Effect_S = (EMAX_COL*COL**H_COL)/(EC50_CS**H_COL+CST**H_COL)  
 
The effect of ceftazidime was modeled to increase the natural elimination of bacteria, Kd, by a Hill-
function. Kmax is the maximal fractional increase in Kd, the value of Kmax will result in a proportional 
increase in Kd. Hill’s constant, H, influences the shape of the effect curve i.e. as the value of H increases 
the slope of the PD function becomes steeper.  
 
Bacterial Killing of ceftazidime/avibactam= 




Neither this equation nor any other considered that assumed a homogenous drug sensitivity throughout 
the inoculum was able to fit the experimental data. Therefore, we employed a “mixture model” in which 
the total bacterial load at any moment is characterized as a mixture of as many as three bacterial 
subpopulations. These populations were allowed to differ only in their initial concentrations (CFU at 






Figure 1. MBM schematic depicting the shift in CAZ KC50 through COL 
disruption of the outer bacterial membrane, and through the β-lactamase 
effect of AVI     
 
Results: 
Static Time-Kill Results: 
For colistin monotherapy many of the strains demonstrated early bacterial killing, especially at some of 
the higher concentrations such as 8 mg/L and 16mg/L. However, around the 4 to 6-hour time point, 
bacterial regrowth began to set in that was similar to the control data at 24 hours. All of the strains 
showed resistance to colistin even though many of the MICs were determined to be less than 0.5 mg/L. 
The ceftazidime/avibactam monotherapy showed faster and more sustained killing than the colistin 
monotherapy group. Many of the strains had 2-3 log-reduction by the 4 to 6-hour time points and had 
no regrowth at all. Regrowth for the ceftazidime/avibactam time kills were seen with MICs greater than 
2mg/L and usually in lower concentrations such as the 16/4 mg/L groups. The most drastic killing effect 
was seen with the combination of colistin and ceftazidime/avibactam. Log-reduction of 3-4 was seen by 
almost all of the strains, with extended killing below the limit of quantification (BLQ) out to 24 hours. 
Regrowth was uncommon, but when it did occur, it happened between the 8 to 24-hour time points 
and, similarly to the monotherapy SCTK studies, were mainly with lower concentrations of drug. MICs 
above 1-2 mg/L were more likely to have regrowth at the 24-hour time points.    
Although there is a similar killing effect between the ceftazidime/avibactam monotherapy treatment 
and the combination treatment, it is important to highlight that the differences are significant (Figure 2). 
At the 24-hour time point for the ceftazidime/avibactam monotherapy, there are still bacterial loads 
thar are above the BLQ line (dotted). Additionally, there is a more significant log-reduction in bacterial 
load when using the combination therapy. To achieve higher rates of treatment success, it is important 
to elicit a killing effect that is quick and has a long duration. In this study, the combination of colistin and 
ceftazidime/avibactam was able to accomplish this through its ability to decrease bacterial load below 




OM- outer membrane 
Mechanism-Based Modeling:   
A mechanism-based PD model of SCTK data was developed to quantitatively characterize the bacterial 
killing and regrowth for both colistin and ceftazidime/avibactam alone and in combination against K. 
pneumoniae. Using a bacterial growth model, monotherapy time-kill data for each antibiotic and the 
final estimates were used to inform the development of the model for the combination therapy (Table 
1).  
Our main focus was to identify the effect of combination therapy on bacterial growth. We found that 
when given together, bacterial killing is drastically increased and sustained with most concentrations 
through 8 hours. When resistance was seen, it did not manifest until the 24-hour time point. The MBM 
was able to capture the reduction in bacterial burden and bacterial regrowth well for all 5 strains (Mean 
R2 =0.974, standard deviation= ±0.02), as shown in Figure 2. The coefficient of determination for the 
strains ranged from 0.92-0.99, showing that the model fits were all very good and there was a less than 
10% variance between each of the models.  
 
 
Figure 2. Time course of bacterial density in response to static concentrations of colistin, ceftazidime/ 
avibactam, and colistin in combination with ceftazidime/avibactam at concentrations used for human 
treatment. The solid lines (–) represent the model fits and the dots (•) represent the observed 
experimental values. The MBM was able to capture the reduction in bacterial burden and rapid 
regrowth well (R2 = 0.974).   
 
 




Kmax,COL  (h-1)  Maximum killing rate 
constant of COL 
16.1 [9.72-18.6]  3.90 [2.38-11.9]  
Kmax,CAZ (h-1)  Maximum killing rate 
constant of CZA 
9.84 [5.29-10.8]  4.04 [3.35-8.01]  
KC50,COL(S) (mg/L)  COL concentration 
resulting in 50% of 
KMAX,COL in the susceptible 
subpopulation  
1.18 [0.10-150]  12.7 [4.95-15.3] 
KC50,COL(R) (mg/L)  COL concentration 
resulting in 50% of 
KMAX,COL in the resistant 
subpopulation  
565 [58.2-2090]  7.53 [3.71-8.03]  
KC50,CAZ(S) (mg/L)  CAZ concentration 
resulting in 50% of 
KMAX,CAZ in the susceptible 
subpopulation  
0.69 [0.28-6.93]  12.1 [4.73-26.6]  
KC50,CAZ(R) (mg/L) CAZ concentration 
resulting in 50% of 
KMAX,CAZ in the resistant 
subpopulation  
163 [60.4-373]  6.54 [4.08-12.2]  
Imax,AVI  (h-1)  Maximum fractional 
decrease of KC50,CAZ by AVI 
β-lactamase  killing effect 
0.58 [0.22-0.66]  46.7 [20.8-127]  
IC50,AVI (mg/L)  AVI concentration causing 
50% of Imax,AVI  
0.12 [0.04-0.32]  9.77 [3.94-29.9]  
Imax,COL,OM (h-1)  Maximum fractional 
decrease of KC50,CAZ by COL 
via outer membrane 
disruption   
0.44 [0.15-0.75]  50.8 [10.3-195]  
IC50,COL,OM (mg/L)  COL concentration causing 
50% of Imax.COL,SYN  
0.64 [0.16-1.75]  12.8 [4.09-27.1]  
LogMF_RS   Log10 mutation frequency 
of sub population resistant 
to COL  
-5.56 [-6.87- -3.72] 1.05 [0.60-4.49] 
LogMF_SR  Log10 mutation frequency 
of sub population resistant 
to CAZ  
-3.88 [-4.32- -1.71] 3.32 [0.92-5.85] 
LogCFU0   
(log10 CFU/ml) 
Initial Inoculum   6.15 [5.87-6.25] 0.87 [0.61-1.11] 
LogCFUm   CFU at which the rate of 
replication is 50% of 
maximum growth velocity  





9.49 [9.20-9.63] 0.29 [0.24-1.07] 
Kd  Killing rate constant  0.3 Fixed18 
Table 1. Model Parameter estimates and CV (%) are reported 
 
Discussion: 
Overall, the mechanism-based model was able to predict the bacterial time kill data well. With some of 
the isolates, the MIC value did not correlate to how we initially thought the bacterial time course would 
appear. For instance, strain 3151 had a MIC of 0.5 mg/L for colistin and 1.0 mg/L for 
ceftazidime/avibactam which made us think that both drugs would have an excellent killing effect. 
However, this wasn’t the case. There was major regrowth for the colistin alone concentrations, and the 
ceftazidime/avibactam monotherapy treatment wasn’t able to drop the bacterial load below the limit of 
quantification. When just relying on MIC to predict bacterial sensitivity, other factors may be missed 
leading to inappropriate dosing. Modeling the killing effect can help to better understand characteristics 
of each strain and to better dose patients accordingly.   
The precision on the final estimates for the MBM were very good for the Kmax and KC50 values. Even the 
higher range values were below 50% showing that each of the five strains had excellent precision. With 
both monotherapy and combination therapy data available, there was much more information the 
model could use to better predict the killing effect of colistin and ceftazidime/avibactam.  
Precision was still good for the parameters involved with avibactam’s effect (Imax,AVI, IC50,AVI) on 
ceftazidime as well. However, one reason the precision is not better is that there was no data available 
with the killing effect of ceftazidime without avibactam. Because of this, it was much harder to gauge 
the effect that avibactam had on the ceftazidime killing. Avibactam inhibits the beta-lactamase 
properties of the Klebsiella bacteria which have a devastating effect on ceftazidime if it is given without 
avibactam. Understanding the killing effects that ceftazidime has by itself would allow us to quantify 
how much more bacterial killing is there is when avibactam is added.  
The maximum fractional decrease of KC50,CAZ by COL via outer membrane disruption (Imax,COL,OM ) was also 
difficult to describe with this model and also had a higher CV% with some of the strains. One thought for 
why this occurred, is due to the lack of killing effect that colistin has on some of the strains, especially 
those that have a higher MIC. If colistin is not able to elicit its killing mechanism of breaking open the 
bacterial cell membrane, then it also isn’t increasing the killing of ceftazidime either. In higher MIC 
strains, colistin isn’t having barely any effect and thus it is almost as if it is removing the parameters 
involved with the outer membrane effect as a whole. In some strains we can quantify the effect and 
some strains we cannot, leading to decreased precision.    
This is a very innovative approach for a few reasons, the first being that by developing a PD model for 
time-kill studies, we can use it to make recommendations about patient dosing without having to enroll 
patients into a study. Modeling this data allows for more freedom in troubleshooting concentrations to 
see which ones we think might need to be achieved to kill specific bacteria. Future simulations derived 
from this PD model will also have an impact on choosing doses for each of the drugs used. Another 
reason that this project is innovative, is that ceftazidime/avibactam is a drug that was only approved by 
the FDA in 2015. In the grand scheme of antibiotics, it is a newer drug that does not have as much 
circulating data as piperacillin/tazobactam or other combination antibiotics. Developing a PD model for 
this drug can be crucial for better understanding its pharmacology and use in combination with other 
antibiotics. 
One limitation to this study is not having multiple time points at each concentration. For each bacterial 
strain there is only one-time point per concentration used. If there is an outlier or any major error in any 
of the time points, we would not know. We can make guesses about whether that time point it correct 
or not, but without additional data at each time point, we have to accept that it is the actual data point 
in the model. Additionally, the lower limit of quantification for the assay involved in this study was a 
LogCFU of 2. There were many data points at 6, 8, or 24 hours that were BLQ. Because there is some 
ambiguity about the actual bacterial load at those time points, it contributes to the error of our model.  
Future directions for this study would be first to try and incorporate the pharmacokinetics of 
ceftazidime/avibactam and colistin into the model. Evaluating in silico pharmacodynamic activity in 
response to clinically relevant exposures for these antibiotics would improve our predicting ability to 
determine what doses should be used to treat infected patients. Additionally, incorporating patient 
specific clinical data, or bacterial strain genomics would also be helpful in painting a full picture of the 
system we are treating. Adding in age, immune function, or bacterial mutations would allow for better 
predicting of outcomes or dosing options. Another future study could be to look at how our model 
would work in tissue infections. This model was built off of data from blood stream infections, but 
measuring its utility in tissue infections would be a great test. Finally, after developing the model 
further, we could compare outcomes of model dosing versus package insert dosing to gauge how well 
this model would work for treating actual patients.  
Overall, the mechanism-based model was able to capture the static time-kill experimental data well and 
help to better understand the effects of each drug in monotherapy and in combination. This information 
will enable us to optimize and translate these antibiotic regimens better suited to treat infections 














1.  Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of 
Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785-796. doi:10.1016/S1473-
3099(13)70190-7 
2.  Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. 
Curr Opin Microbiol. 2010;13(5):558-564. doi:10.1016/j.mib.2010.09.006 
3.  Martinez RM, Wolk DM. Bloodstream Infections. In: Diagnostic Microbiology of the 
Immunocompromised Host, Second Edition. Vol 4. American Society of Microbiology; 2016:653-689. 
doi:10.1128/microbiolspec.DMIH2-0031-2016 
4.  Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM. Population burden of long-term survivorship after 
severe sepsis in older Americans. J Am Geriatr Soc. 2012;60(6):1070-1077. doi:10.1111/j.1532-
5415.2012.03989.x 
5.  Stevenson M, Pandor A, James MM-S, et al. Background and definition of the decision problem. 
2016. https://www.ncbi.nlm.nih.gov/books/NBK368614/. Accessed January 19, 2019. 
6.  Prescott HC, Langa KM, Liu V, Escobar GJ, Iwashyna TJ. Increased 1-Year Healthcare Use in 
Survivors of Severe Sepsis. Am J Respir Crit Care Med. 2014;190(1):62-69. doi:10.1164/rccm.201403-
0471OC 
7.  Tacconelli E, Carrara E, Savoldi A, Kattula D, Burkert F. Global Priority List of Antibiotic-Resistent 
Bacteria to Guide Research, Discovery and Development of New Antibiotics.; 2017. 
https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-
ET_NM_WHO.pdf?ua=1. Accessed January 19, 2019. 
8.  Neuner EA, Yeh J-Y, Hall GS, et al. Treatment and outcomes in carbapenem-resistant Klebsiella 
pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011;69(4):357-362. 
doi:10.1016/j.diagmicrobio.2010.10.013 
9.  Boucher HW, Talbot GH, Benjamin DK, et al. 10 x ’20 Progress--Development of New Drugs 
Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America. Clin 
Infect Dis. 2013;56(12):1685-1694. doi:10.1093/cid/cit152 
10.  van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of 
Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2017;66(2):163-171. 
doi:10.1093/cid/cix783 
11.  Rao G, Li J, Garonzik S, Nation R, Forrest A. Assessment and modelling of antibacterial 
combination regimens. Clinical Microbiology and Infection. 2018;24(7):689-696. 
doi:10.1016/j.cmi.2017.12.004. 
12.  Allergan G. AVYCAZ Highlights of Prescribing Information.; 2018. 
13. Avycaz (ceftazidime/avibactam) [prescribing information]. Irvine, CA: Allergan USA Inc; March 
2019. 
14. D’Argenio, D.Z., A. Schumitzky and X. Wang. ADAPT 5 User’s Guide: 
Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los 
Angeles, 2009. 
15.  Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-
processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 13:201–211. 
16. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with 
lipopolysaccharide. Biochemistry 1979;18:4425-30. 
17. Aszodi J, Fromentin C, Lampilas M, et al. Aventis Pharma SA, assignee Heterocyclic compounds 
which are active as inhibitors of β-lactamases, 2003. 2003 Jan 27; International Patent number 
PCT/FR2003/000243.  























I would like to recognize Patrick Hanafin and the rest of the Rao lab for their teachings. I would also like 
to thank Julie Dumond and Craig Lee for their assistance with the RASP program and for helping to direct 
it. Lastly, I would like to thank Alan Forrest for introducing me to these modeling concepts. 
Funding Support 
“The authors have no funding support to disclose” 
Conflicts of Interest 
“The authors have no conflicts of interest to disclose” 
Dissemination Plan 
This work was accepted by the American Conference on Pharmacometrics. The Conference was held on 
October 20-23 2019. 
This work is a part of a bigger project that will be submitted to Antimicrobial Agents and Chemotherapy 
or Clinical Microbiology and Infection. 
